Kidney cancer affects over 80,000 Americans annually, with renal cell carcinoma as the dominant type. Benjamin R. Lee, MD, MBA, outlines current AUA guideline recommendations, including when to…
Dr. Allison Betof Warner from Stanford University joins Rahul Gosain, MD and Rohit Gosain, MD, on the Oncology Brothers podcast to discuss melanoma treatment. The conversation covers the…
Nancy A. Kernan, MD, Assistant Chief, Pediatric Bone Marrow Service, Director, Unrelated Donor Program, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the importance of SuperSibs!, a national…
At the American Society of Clinical Oncology meeting, data from a small retrospective analysis suggest that diabetic patients with breast cancer had significantly higher rates of response to…
Douglas S. Hawkins, MD, Associate Professor, Pediatrics, Children’s Hospital and regional Medical Center, Seattle WA, discusses pharmacogenomics of chemotherapy. For more information on this physician visit: SeattleChildrens.org .
As presented at ASCO, second-line bevacizumab (Avastin) as monotherapy has been associated with a 28% response rate and an overall survival edge for refractory glioblastoma. Also presented at…
Mary Wright, MD, Associate Professor & Director, Breast Center, Section of Breast Surgery, Department of Surgery, Tulane University School of Medicine, discusses Tulane’s Breast Cancer Center. References and…
A meta-analysis of observational studies showed that oral estrogen, but not transdermal estrogen, increased the risk of venous thromboembolism. References and Resources Canonico M, Plu-Bureau G, Lowe GD,…
Using a multivariate regression analysis, it has been shown that people with a common genetic mutation have up to twice the risk of lung cancer as do people…
Vivek K. Mehta, MD, Radiation Oncologist, Director, Center for Advanced Targeted Radiotherapies, Department of Radiation Oncology, Swedish Cancer Institute, Seattle, WA, discusses volumetric arc therapy. References and Resources…
A recent study shows that malignant high-grade PINs have a greater expression of PTOV1 (prostate tumor overexpressed-1) compared with benign lesions, and as expression of PTOV1 decreased, so…
Dan Labriola, ND, Director, Naturopathic Services, Swedish Cancer Institute, Seattle, WA, discusses complementary therapy with the treatment of cancer. References and Resources Eliott JA, Kealey CP, Olver IN.…
